Non Animal Testing Database

In silico analysis for antiviral therapies against SARS-CoV-2

December 2020
University of Tübingen, Tübingen, Germany
The authors used a computational approach to discover new metabolic antiviral targets against SARS-CoV-2. An integrated host-virus genome-scale metabolic model of human alveolar macrophages and SARS-CoV-2 identified the enzyme guanylate kinase as one potential target, showing that its knock-out prevents virus growth, while not affecting the host. Since guanylate kinase inhibitors are described in the literature, the authors propose the assessment of their potential therapeutic effects for SARS-CoV-2 infections.
FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2
Alina Renz, Andreas Dräger
Added on: 01-06-2021
Back to Top
English German

Warning: Internet Explorer

The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.

Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!